Ocata Therapeutics Receives Two New Patents For Immune-Modulatory Cell Technology

Ocata Therapeutics, Inc. , a leader in the field of Regenerative OphthalmologyTM, today announced that the United States Patent and Trademark Office issued two U.S. Patents, Nos. 8,962,321 and 8,961,956, directed to the Company's Hemangio-derived Mesenchymal Cells .

http://ift.tt/1woYLy6